Dako Enters into an Additional Collaboration with Amgen on Developing a Companion Diagnostic Test (pharmDxTM) for an Investigational Cancer Therapy in Clinical Development
(Thomson Reuters ONE) -
Dako, a world leading independent cancer diagnostic supplier with 45 years of
experience in pathology, announced today that it has entered into a new
collaboration agreement with Amgen Inc. (Nasdaq: AMGN) on the development of a
diagnostic test for an Amgen cancer drug candidate in clinical development.
"It is Dako's mission to fight cancer. Hence, we are pleased to be chosen as
Amgen's partner once again for the development of companion diagnostics linked
to Amgen's investigational targeted therapies," says Lars Holmkvist, Dako's
chief executive officer.
In January 2012, Dako announced a collaboration agreement with Amgen Inc.
introducing a new business model which supports the concurrent development of
drug and diagnostics for a rare but deadly cancer - something that up to this
point has been difficult to achieve in the industry.
"This new collaboration with Amgen underlines Dako's commitment to advance
personalized medicine in cancer treatment as the selection of patients most
likely to benefit from a specific treatment will increase the probability of
therapeutic success for cancer patients suffering," Lars Holmkvist adds.
Today's news comes on the heels of several pharmDx(TM) collaborative agreements
recently announced by Dako.
The demand for personalized medicine is increasing with the recognition that it
may provide a way to improve patient care and manage healthcare costs by
targeting treatments to individuals more likely to benefit from specific
therapies.
Media contact
Maia Fredtoft Søchting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make accurate diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1,000 people and being present in more than 80 countries, Dako covers
essentially all of the anatomic pathology markets globally. Dako is owned by
private equity fund EQT V.www.dako.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1587603]
Unternehmensinformation / Kurzprofil:
Datum: 20.02.2012 - 16:00 Uhr
Sprache: Deutsch
News-ID 116414
Anzahl Zeichen: 2935
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 229 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako Enters into an Additional Collaboration with Amgen on Developing a Companion Diagnostic Test (pharmDxTM) for an Investigational Cancer Therapy in Clinical Development"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
